For example, a human anti‐IL‐4Rα monoclonal antibody which interrupts signaling of both IL‐4 and IL‐13 has demonstrated convincing efficacy in controlling moderate‐to‐severe atopic dermatitis,25 allergic asthma,26 and nasal polyps.27 This evidence concerns the gene IL4 and nasal cavity polyp.